1. Home
  2. ONEN vs TLSA Comparison

ONEN vs TLSA Comparison

Compare ONEN & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ONEN

ONE Nuclear Energy Inc. Common Stock

N/A

Current Price

$1.47

Market Cap

133.6M

Sector

N/A

ML Signal

N/A

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$0.62

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ONEN
TLSA
Founded
N/A
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.6M
145.1M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
ONEN
TLSA
Price
$1.47
$0.62
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $7.98
AVG Volume (30 Days)
58.6K
★ 509.7K
Earning Date
12-23-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$0.57
52 Week High
$3.07
$1.90

Technical Indicators

Market Signals
Indicator
ONEN
TLSA
Relative Strength Index (RSI) 43.47 33.00
Support Level N/A $0.57
Resistance Level $1.71 $1.21
Average True Range (ATR) 0.18 0.08
MACD 0.05 -0.02
Stochastic Oscillator 43.44 17.65

Price Performance

Historical Comparison
ONEN
TLSA

About ONEN ONE Nuclear Energy Inc. Common Stock

One Nuclear Energy Inc is a development-stage independent power producer focused on developing reliable, high-density, low-carbon baseload electricity and heat generation projects to support energy supply needs in the digital economy. The company's objective is to serve a range of energy-intensive customers across multiple sectors, including data centers, industrial manufacturing, refineries, desalination facilities, and other critical infrastructure users.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: